Evolus AI Stock Analysis
Want to see EOLS full AI Analyst Report?
Evolus (EOLS) AI Stock Analysis
Evolus
(NASDAQ:EOLS)
The score is held back primarily by financial risk (negative equity, elevated debt, and still-negative profitability) and weak technical momentum (below key moving averages with negative MACD). Offsetting these, the earnings call provided constructive signals via reaffirmed growth and margin guidance, improved expense outlook, and continued positive adjusted EBITDA, which lifts the overall score despite limited valuation support from a negative P/E and no dividend.
Evolus (EOLS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $438.83M
- Dividend Yield
- ―
- Average Volume (3M)
- 922.02K
- Price to Earnings (P/E)
- -14.2
- Beta (1Y)
- 1.25
- Revenue Growth
- 13.87%
- EPS Growth
- 48.13%
- Country
- US
- Employees
- 353
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Evolus Business Overview & Revenue Model
Company Description
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified...
How the Company Makes Money
Evolus makes money primarily by selling Jeuveau to the aesthetic medical market (e.g., dermatologists, plastic surgeons, medical spas, and other healthcare providers) who purchase the product and administer it to patients. Revenue is recognized from...
Evolus Earnings Call Summary
The call was strongly positive, supported by 13% third-quarter revenue growth, double-digit global toxin growth, more than 40% Evolysse growth, expanding customer and consumer engagement, four consecutive quarters of positive adjusted EBITDA, lower operating expense guidance, and reaffirmed 2028 financial targets. The main challenges were softer consumer confidence, a regulatory untitled letter, seasonally lower third-quarter purchasing volumes, higher planned fourth-quarter expenses, a lower cash balance, and the absence of Sculpt revenue in 2026. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Evolus continues to expect full year revenue between $330 million and $337 million, representing 11% to 13% growth over 2025, with the annual outlook implying a sequential increase in the fourth quarter; full year adjusted gross profit margin remains 67% to 67.5%, while full year non-GAAP operating expenses are expected to be between $210 million and $213 million, from the prior range of $212 million to $216 million, representing approximately flat to 2% growth over 2025, and full year adjusted EBITDA margin remains low to mid-single-digit. Evolysse and Estyme injectable HA gels are expected to contribute 10% to 12% of full year revenue, with no revenue contribution from Evolysse Sculpt in 2026; Evolysse Sculpt approval is anticipated in the fourth quarter of 2026 and launch in 2027, Lips submission is expected before the year-end with launch in early 2028, Profhilo approval is anticipated around 2030, and 2028 targets remain annual revenue of $450 million to $500 million and adjusted EBITDA margins of 13% to 15%.
Evolus Financial Statement Overview
Summary
Strong multi-year revenue growth and healthy ~65–70% gross margins are positives, and losses and cash flow have improved (TTM free cash flow positive). However, profitability remains negative (TTM net margin ~-9.6%, negative operating profit) and the balance sheet is a major constraint with negative equity and sizable debt, increasing refinancing/dilution risk.
Income Statement
46NeutralBalance Sheet
28NegativeCash Flow
39Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 325.47M | 297.18M | 266.27M | 202.09M | 148.62M | 99.67M |
| Gross Profit | 214.52M | 192.76M | 182.30M | 140.53M | 89.77M | 56.14M |
| EBITDA | -4.42M | -22.53M | -25.00M | -41.81M | -53.08M | -39.06M |
| Net Income | -31.11M | -51.64M | -50.42M | -61.69M | -74.41M | -46.81M |
Balance Sheet | ||||||
| Total Assets | 283.82M | 225.87M | 232.57M | 189.00M | 177.98M | 257.48M |
| Cash, Cash Equivalents and Short-Term Investments | 41.70M | 53.83M | 86.95M | 62.84M | 53.92M | 146.26M |
| Total Debt | 165.59M | 155.00M | 129.98M | 126.55M | 74.42M | 74.74M |
| Total Liabilities | 321.64M | 248.97M | 227.05M | 209.69M | 159.48M | 175.61M |
| Stockholders Equity | -37.81M | -23.11M | 5.52M | -20.69M | 18.50M | 81.88M |
Cash Flow | ||||||
| Free Cash Flow | -7.32M | -50.72M | -19.47M | -35.63M | -87.85M | -34.36M |
| Operating Cash Flow | -2.65M | -42.27M | -18.00M | -34.01M | -84.91M | -33.39M |
| Investing Cash Flow | -6.17M | -8.45M | -4.82M | -1.63M | -2.94M | 4.03M |
| Financing Cash Flow | 7.43M | 17.34M | 47.41M | 44.64M | -4.15M | 73.05M |
Evolus Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EOLS, the sentiment is Negative. The current price of 6.63 is below the 20-day moving average (MA) of 7.19, below the 50-day MA of 7.56, and above the 200-day MA of 6.38, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 39.85 is Neutral, neither overbought nor oversold. The STOCH value of 41.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EOLS.
Evolus Risk Analysis
Evolus disclosed 54 risk factors in its most recent earnings report. Evolus reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksEvolus Peers Comparison
Overall Rating
PCRX70Outperform
SNOA54Neutral
DERM51Neutral
EOLS48Neutral
ORGO42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | $1.46B | 38.31 | 5.53% | ― | 3.70% | 101.62% | |
| 54Neutral | $4.46M | -0.94 | -36.40% | ― | 38.69% | 58.68% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $104.43M | -20.28 | -16.07% | ― | 17.03% | 49.40% | |
| 48Neutral | $438.83M | -14.24 | 103.19% | ― | 13.87% | 48.13% | |
| 42Neutral | $104.24M | -0.68 | -46.25% | ― | -24.33% | -1171.44% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EOLS | Evolus, Inc. | 6.63 | -0.40 | -5.69% | |
| SNOA | Sonoma Pharmaceuticals, Inc. | 0.88 | -2.65 | -75.07% | |
| PCRX | Pacira | 36.48 | 12.09 | 49.57% | |
| ORGO | Organogenesis Holdings | 0.80 | -4.72 | -85.45% | |
| DERM | Journey Medical Corporation | 3.70 | -4.25 | -53.46% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
